Bayer starts Phase III trial in non-small cell lung cancer
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
First patient enrolled in the Phase III SOHO-02 trial of investigational agent BAY 2927088 in treatment-naïve patients with advanced NSCLC with HER2-activating mutations
Critical resources will help Genvor to grow and scale biological crop protection products and innovative trait technologies
The low-profile, 2” Disc Top Lite closure offers lighter weight combined with premium customization options
Launches Opentop 40, Opentop D, Opentop L, Opentop Dsr and Cefix 200 which are available for sale
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
PfizerForAll works within the existing healthcare system and through a growing network of partners to simplify access via established channels and to close gaps in care
Patni brings over 25 years of distinguished experience in the pharmaceutical industry
In a Phase 3 trial, Pfizer and BioNTech’s combination vaccine candidate against influenza and COVID-19 met one of its two primary immunogenicity objectives
Subscribe To Our Newsletter & Stay Updated